Skip to Content
Merck
CN

Key Documents

View All Documentation

1719000

USP

Warfarin

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

4-Hydroxy-3-(3-oxo-1-phenylbutyl)coumarin, Coumafene

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C19H16O4
CAS Number:
81-81-2
Molecular Weight:
308.33
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
329751510
MDL number:
MFCD00006854
Beilstein/REAXYS Number:
8868198
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

grade

pharmaceutical primary standard

API family

warfarin

manufacturer/tradename

USP

mp

162-164 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

CC(=O)CC(c1ccccc1)C2=C(O)c3ccccc3OC2=O

InChI

1S/C19H16O4/c1-12(20)11-15(13-7-3-2-4-8-13)17-18(21)14-9-5-6-10-16(14)23-19(17)22/h2-10,15,21H,11H2,1H3

InChI key

PJVWKTKQMONHTI-UHFFFAOYSA-N

Gene Information

human ... VKORC1(79001)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Warfarin USP Reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Warfarin Sodium
  • Warfarin Sodium Tablets
  • Warfarin Sodium for Injection

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Legal Information

Disclaimer

Sales restrictions may apply.

signalword

Danger

Hazard Classifications

Acute Tox. 1 Dermal - Acute Tox. 1 Inhalation - Acute Tox. 2 Oral - Aquatic Chronic 2 - Repr. 1A - STOT RE 1 Oral

target_organs

Blood

Storage Class

6.1A - Combustible acute toxic Cat. 1 and 2 / very toxic hazardous materials

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Regulatory Information

非剧毒-急性毒性1
农药列管产品

This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

ACP Journal Club: mechanical left atrial appendage closure was noninferior and superior to warfarin in atrial fibrillation.
Vinai Bhagirath et al.
Annals of internal medicine, 162(8), JC4-JC4 (2015-04-22)
Ye Wang et al.
Cardiovascular drugs and therapy, 28(6), 575-585 (2014-10-17)
This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in Singapore. A Markov model was constructed to compare the lifetime costs, quality-adjusted life-years (QALYs)
Tomasz Baron et al.
Heart (British Cardiac Society), 101(2), 101-106 (2014-10-22)
We aimed to assess differences in incidence, clinical features, current treatment strategies and outcome in patients with type 2 vs. type 1 acute myocardial infarction (AMI). All 20 138 hospitalisations in Sweden with a diagnosis of AMI registered during 2011 in
Minoru Yabuta et al.
Journal of vascular and interventional radiology : JVIR, 25(9), 1406-1412 (2014-05-24)
To evaluate retrospectively the long-term outcomes of percutaneous transhepatic balloon angioplasty performed for portal vein stenosis (PVS) after pediatric living donor liver transplantation (LDLT). Between October 1997 and December 2013, of 527 pediatric patients (age < 18 y) who underwent
Benjamin A Steinberg et al.
Circulation, 131(5), 488-494 (2014-12-17)
Temporary interruption of oral anticoagulation for procedures is often required, and some propose using bridging anticoagulation. However, the use and outcomes of bridging during oral anticoagulation interruptions in clinical practice are unknown. The Outcomes Registry for Better Informed Treatment of
View All Related Papers

Global Trade Item Number

SKUGTIN
1719000-200MG04061838751331

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service